Acute Asthma

Asthma Asthma represents a lasting inflammatory airway condition characterized by hyper-responsiveness of the airways accompanied by repeated episodes of breathlessness, coughing, wheezing, and chest tightness. Such episodes have commonly been linked to airflow blocks which can be spontaneously reversed or sometimes require medication. Roughly three hundred million individuals worldwide suffer from asthma. Among children, boys exhibit greater asthma risk whilst among adults, women exhibit greater prevalence.

A grasp of the condition’s pathophysiology (both acute and chronic forms) will facilitate an understanding of how to diagnose and treat patients suffering from it. Experts’ asthma pathogenesis knowledge has greatly evolved during the past twenty-five years with scholars discovering several phenotypes of the condition (Lynn & Kushto-Reese, 2015). Pathophysiology of Acute Asthma Acute asthma intensification, or asthmatic attacks, take place through binding of inhaled antigens to mast cells performing immunoglobulin E (IgE).

These cells start degranulating, thereby releasing bradykinins, prostaglandins, leukotrienes, platelet-activating factors, histamine, interleukins, and other inflammatory mediators which lead to airway muscle bronchospasms and edema owing to enhanced capillary permeability. Further, goblet cells’ enhanced mucus secretion constricts the patient’s airway. Antigens are spotted by dendritic cells and a signal is sent to the Th2 cells that secrete interleukin -4, among other things. Such interleukins stimulate IgE production by B cells.

Additionally, Th2 cells may generate IL-5 that stimulates eosinophils, responsible for creating eosinophilic cationic and significant proteins which lead to respiratory epithelium damage. A number of inflammatory cells (e.g., neutrophils, IgE) play a role in causing inflammation and obstructing the airway (Conley, 2017). Pathophysiology of Chronic Asthma The term ‘chronic asthma’ largely revolves around asthma’s long-run implications. Chronic asthmatics are at an advanced stage of the condition, marked by lasting damage.

This condition is usually characterized by greater type 2 inflammation sensitivity, vitiated lung growth, increased viral infection susceptibility, or bacterial colonization. Among patients at this stage, dendritic cells, eosinophils, neutrophils, basophils, lymphocytes, B lymphocytes, mast cells and T helper 2 cells stimulate airway hyper-responsiveness and intractable bronchial mucosa inflammation (Conley, 2017). Chronic and acute asthma, to some extent, resemble one another in terms of symptoms and elementary treatment. But the key difference between the two is how long the episode lasts.

Acute asthma is temporary whilst chronic asthmatic attacks are prolonged and can continue for a long period (MyAsthmaGuide, 2018). Pathmavathi, Subash and Sumangali’s (2013) arterial blood gas (ABG) examination on a total of forty subjects aimed at assessing ABG status among chronic and acute bronchial asthmatics. Acute asthmatics’ typical ABG pattern revealed hypoxaemia accompanied by respiratory acidosis among a fairly large share of subjects and hypoxaemia accompanied by respiratory alkalosis among the remaining (i.e. subjects depicting abnormality in ABG patterns).

Meanwhile, chronic asthmatics exhibited hypoxaemia accompanied by respiratory alkalosis among a fair share of subjects; however, no patient exhibited respiratory acidosis. Role of Ethnicity Davidson, Sheikh and Liu’s (2010) Scottish research explored ethnicity impacts on asthma, as well as probable justifications for unequal disease burden among minority groups. Authors reached the conclusion that health-related attitudes and beliefs, behaviors, lack of communication, prior experiences, poor health literacy, fairly low socioeconomic standing and care quality concerns were probable factors responsible for ethnic disparities and unequal disease burden among ethnic minorities.

Ethnicity has complex effects on asthma incidence. Asthma incidence can differ based on individuals’ nativity, ethnic classification, and time elapsed since migration (in case of migrants). For instance, Mexican Hispanics not born in the US display lower asthma incidence than US Hispanics. Likewise, non-British born individuals display decreased fresh/first asthma consultation risks in comparison to UK-born members of their ethnic group. The above discovery indicates environmental condition (diet, housing, etc.) and exposure (allergen, pollutant, etc.) modifications or behavioral (e.g.

smoking) or lifestyle modifications after migration may modify susceptibility, particularly among early life migrants. Early-life chronic infection exposure is deemed responsible for greater asthma incidence among ethnic minority migrants (Davidson, Liu & Sheikh, 2010). As asthma’s symptoms typically do not surface during diagnosis, patient medical history offers physicians the best indications for determining what ailment plagues the patient. When collecting this information, ascertaining symptoms as well as their time of occurrence is vital. Family history must cover patient genetics, history of known allergies, and ethnicity/race (Myers, 2018).

Treatment Recent O3 and NO2 exposure can lower SABA response when producing bronchodilation amongst Mexican child asthmatics residing in highly-polluted areas. All the same, severe asthmatics may most likely experience respiratory symptoms upon air pollutant exposure, in spite of receiving steroid treatment (Lewis, Robins & Mentz, 2013). Medical care of asthmatics covers acute asthma attack treatment and chronic symptom control (these include exercise-induced and night-time nocturnal asthma symptoms).

Pharmacologic asthma management covers control agent usage, including inhaled corticosteroids, theophylline, beta-agonists, anticholinergics and other long-acting bronchodilators), leukotriene modifiers, anti-IL-5 antibodies and anti-IgE antibodies (omalizumab). Medications capable of providing relief to asthma patients include ipratropium, short-acting bronchodilators, and systemic corticosteroids. A step-wise asthma management strategy (step-down wherever possible and step-up if required) is still recommended by the present guidelines; however, it is currently divided into the following three age-based groups: 0-4 years, 5-11 years, and 12+ years.

Rapid relief medicines like rapid-acting ?2 agonists may be administered/prescribed to all patients as required for alleviating symptoms. Treatment.